Introduction:
Lonza and Oxford Nanopore Technologies have partnered to expedite the analysis of mRNA. Lonza will use Oxford Nanopore’s sequencing technology to analyze mRNA samples, which will help accelerate the development and manufacturing processes for mRNA-based therapeutics.
- Lonza and Oxford Nanopore Technologies have partnered to improve the analysis of mRNA samples.
- Oxford Nanopore’s sequencing technology will be used by Lonza to analyze mRNA samples, allowing for faster development and manufacturing processes.
- This partnership will lead to increased efficiency in the production of mRNA-based therapeutics.
- The collaboration between Lonza and Oxford Nanopore Technologies will contribute to the advancement of the biotechnology industry as a whole.
- The use of Oxford Nanopore’s technology for mRNA analysis has the potential to revolutionize the field and enable further innovations in the development of therapeutics.
Conclusion:
The partnership between Lonza and Oxford Nanopore Technologies is set to expedite the analysis of mRNA samples, leading to faster development and manufacturing processes for mRNA-based therapeutics. This collaboration has the potential to revolutionize the biotechnology industry and drive further advancements in the field. Overall, this innovative partnership will contribute to the advancement of the field and the production of more efficient therapeutics.
